XTNT - Xtant Medical Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.5000
-0.0800 (-5.06%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.5800
Open1.5800
Bid1.5100 x 1000
Ask1.5500 x 2900
Day's Range1.4500 - 1.5800
52 Week Range1.4200 - 4.7500
Volume9,988
Avg. Volume5,524
Market Cap19.743M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-4.8080
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • Hedge Funds Watching Xtant Medical Holdings, Inc. (XTNT) From Afar
    Insider Monkey

    Hedge Funds Watching Xtant Medical Holdings, Inc. (XTNT) From Afar

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • GlobeNewswire

    Xtant Medical Announces Third Quarter 2019 Financial Results

    BELGRADE, Mont., Nov. 07, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • GlobeNewswire

    Xtant Medical to Issue Third Quarter 2019 Financial Results on November 7, 2019

    BELGRADE, Mont., Nov. 04, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • Should You Investigate Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) At US$2.25?
    Simply Wall St.

    Should You Investigate Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) At US$2.25?

    Xtant Medical Holdings, Inc. (NYSEMKT:XTNT), which is in the medical equipment business, and is based in United...

  • GlobeNewswire

    Xtant Medical to Feature Innovative Product Offering at the CNS Annual Meeting

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, will feature its recently announced Intice™-C Titanium Cervical Interbody Spacer, Atrix-C Union™ Cervical Interbody Spacer and Calix®-C PC Plasma Coated PEEK Implant products at the Congress of Neurological Surgeons (CNS) Annual Meeting, which will be held October 19 – 23 in San Francisco. Kevin Brandt, Chief Commercialization Officer of Xtant Medical, said, “As we have established in our past, providing neurosurgeons with unique products to treat patients with a variety of spinal disorders, particularly in the cervical spine, is a key objective for Xtant. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.

  • GlobeNewswire

    Xtant Medical Names Sean Browne President and Chief Executive Officer

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Sean Browne as President and Chief Executive Officer, effective immediately. “Sean has an extensive track record of success as a medical device executive, and his expertise spans diverse business stages, product segments, and financing structures,” said Jeff Peters, Chairman of the Board of Xtant Medical. “His demonstrated ability to strategically build and guide business teams and manage critical business functions will be an asset to Xtant as the company continues to advance its turn-around strategy, which includes enhancing the operational effectiveness of its business and investing in technologies and personnel that are critical for enabling future growth.

  • GlobeNewswire

    Xtant Medical Showcases Continued Innovation with Three New Product Introductions at NASS 2019

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, plans to introduce three new products at the North American Spine Society (NASS) 2019 Annual Meeting, which will be held September 25 – 28 in Chicago. Meeting attendees can visit Booth #2916 to learn about Xtant Medical’s latest product innovation. Kevin Brandt, Chief Commercialization Officer of Xtant Medical, said, “Even as we celebrate 20 years of meeting patient and physician need in the spine and orthopedic indications, we continue to develop and commercialize new products that are designed to improve clinical outcomes.

  • Thomson Reuters StreetEvents

    Edited Transcript of XTNT earnings conference call or presentation 8-Aug-19 1:00pm GMT

    Q2 2019 Xtant Medical Holdings Inc Earnings Call

  • GlobeNewswire

    Xtant Medical Announces Second Quarter 2019 Financial Results

    BELGRADE, Mont., Aug. 08, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • GlobeNewswire

    Xtant Medical to Issue Second Quarter 2019 Financial Results on August 8, 2019

    BELGRADE, Mont., Aug. 01, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • GlobeNewswire

    Xtant Medical Announces NYSE American Acceptance of Plan to Regain Compliance with Continued Listing Standards

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that NYSE Regulation has accepted the Company’s plan to regain compliance with the NYSE American continued listing standards relating to stockholders’ equity. Xtant Medical submitted its plan on May 3, 2019, and has been granted a plan period through October 4, 2020. The listing of the Company’s common stock will continue pursuant to an extension during the plan period, during which time the Company will be subject to periodic review to determine whether it is making progress consistent with the accepted plan.

  • Thomson Reuters StreetEvents

    Edited Transcript of XTNT earnings conference call or presentation 15-May-19 1:00pm GMT

    Q1 2019 Xtant Medical Holdings Inc Earnings Call

  • Does Market Volatility Impact Xtant Medical Holdings, Inc.'s (NYSEMKT:XTNT) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Xtant Medical Holdings, Inc.'s (NYSEMKT:XTNT) Share Price?

    If you own shares in Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) then it's worth thinking about how it contributes to...

  • GlobeNewswire

    Xtant Medical Announces First Quarter 2019 Financial Results

    BELGRADE, Mont., May 15, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • GlobeNewswire

    Xtant Medical to Issue First Quarter 2019 Financial Results on May 15, 2019

    BELGRADE, Mont., May 08, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • Thomson Reuters StreetEvents

    Edited Transcript of XTNT earnings conference call or presentation 1-Apr-19 1:00pm GMT

    Q4 2018 Xtant Medical Holdings Inc Earnings Call

  • GlobeNewswire

    Xtant Medical Receives Noncompliance Notice from NYSE American

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced receipt of notification from the NYSE American that the Company is not in compliance with certain NYSE American continued listing requirements relating to stockholders’ equity. NYSE American indicated the Company is not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide due to negative stockholders’ equity of $43,772,000 as of December 31, 2018 and net losses in five of the most recent fiscal years.  The Company’s stockholders’ equity was negatively affected in the fourth quarter 2018 by $48.1 million in non-cash impairment charges to goodwill and intangibles attributed to the X-Spine acquisition.

  • GlobeNewswire

    Xtant Medical Announces Fourth Quarter and 2018 Financial Results

    BELGRADE, Mont., April 01, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • GlobeNewswire

    Xtant Medical Announces Amendments and Extension of Credit Facility

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has executed the Second Amended and Restated Credit Agreement with affiliates of OrbiMed Advisors. The Second Amended and Restated Credit Agreement provides for up to an additional $10.0 million of borrowing availability via an incremental delayed draw term loan, extends the maturity date from July 31, 2020 to March 31, 2021, and extends the period during which no interest accrues until March 31, 2020, among other provisions. Xtant will issue warrants to the OrbiMed affiliates for the purchase of an aggregate of 1.2 million shares of Xtant common stock.

  • GlobeNewswire

    Xtant Medical to Issue Fourth Quarter and Full Year 2018 Financial Results on April 1, 2019

    BELGRADE, Mont., March 28, 2019 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of.

  • GlobeNewswire

    Xtant Medical Announces Appointment of New Senior Sales Leaders

    Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the recent additions of five senior sales executives: Dana Lyons, Vice President of US Sales, Jamey Rottman, Regional Vice President, Mid Atlantic, Chris Cochran, Regional Vice President, South East, John Eekhof, Regional Vice President, North East, and Luke Armand, Regional Vice President, West.